What the BUPE Act Means for Better Addiction Treatment Congressman Paul D. Tonko (D-NY) and Senator Martin Heinrich (D-NM) announced in early October the introduction of a bill known as the Broadening Utilization of Proven and Effective Treatment for Recovery, or BUPE Act. The BUPE Act is a powerful legislative tool that can improve
The U.S. Food and Drug Administration (FDA) has approved BRIXADI, also known as buprenorphine, for people with moderate to severe opioid use disorder. The drug is an extended-release injection for subcutaneous use (CIII), meant to be taken weekly or monthly at a healthcare provider’s office. Brixadi is a form of Medication-Assisted Treatment meant to help
Far too few people are getting the benefit of Medication-Assisted Treatment in America, even though the FDA considers it the gold standard for people with opioid use disorder. While stigma still creates barriers within the medical system, pharmacists may play a unique role in helping access life-changing medications such as Suboxone, also known as buprenorphine.
The Biden administration announced today that they are expanding access to Medication-Assisted Treatment drug Suboxone, also known as Buprenorphine. Expanding access means that doctors will administer the medications to patients who need them, even in the emergency room. What Does Suboxone Treat? Suboxone is usually taken as a tablet or film daily. The drug, also
Medication-assisted Treatment (MAT) can be a lifeline for those who are addicted to opioids and struggle with long-term cravings and short-term withdrawal symptoms. However, research by NPR shows that doctors and pharmacists mistrust the drug, resulting in few people seeking help with addiction gaining access to it. Doctors Have Little Incentive to Prescribe Buprenorphine Buprenorphine,
Vivitrol, a drug meant to help ex-opioid users stay clean, has finally been shown to be able to control cravings just as much as its competition, according to a new study sponsored by the National Institute on Drug Abuse. This study is the largest head-to-head study to date between two leading drugs - a monthly
The Food and Drug Administration is looking to expand medication-assisted opioid treatment, a type of treatment that often has a stigma attached to it due to being misunderstood. Much of this stigma is ill-suited, FDA Commissioner Scott Gottlieb told a U.S. House committee last Wednesday, and his agency is taking action to make these drugs
Cigna Corp, a major health insurer across the nation with millions customers, took steps this week to make it easier for their clients to get help with opiate addictions. The health insurer announced Friday that it was discontinuing its policy of requiring doctors to seek authorization before commencing treatment for opioid addicts, helping clear an
